Compare HRTG & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRTG | CSTL |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 670.9M | 722.8M |
| IPO Year | 2014 | 2019 |
| Metric | HRTG | CSTL |
|---|---|---|
| Price | $26.50 | $23.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $33.50 | ★ $45.50 |
| AVG Volume (30 Days) | ★ 355.6K | 334.4K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 214.43 | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $847,330,000.00 | $344,229,000.00 |
| Revenue This Year | $7.50 | $2.42 |
| Revenue Next Year | $6.74 | $12.69 |
| P/E Ratio | $23.34 | ★ N/A |
| Revenue Growth | ★ 3.71 | 3.66 |
| 52 Week Low | $16.83 | $14.59 |
| 52 Week High | $31.98 | $44.28 |
| Indicator | HRTG | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 55.41 | 54.29 |
| Support Level | $25.28 | $23.21 |
| Resistance Level | $27.73 | $24.00 |
| Average True Range (ATR) | 1.04 | 0.96 |
| MACD | 0.07 | -0.08 |
| Stochastic Oscillator | 56.37 | 43.07 |
Heritage Insurance Holdings Inc is a regional property and casualty insurance company that offers a variety of personal and commercial insurance products. Through its subsidiaries, Heritage Property & Casualty Insurance, Narragansett Bay Insurance, and Zephyr Insurance, the company issues personal residential property insurance across various states in the U.S. It also offers commercial residential insurance predominantly for its Florida properties. Heritage Insurance manages insurance underwriting, customer services, actuarial analysis, distribution, and claims processing internally. The company operates in Alabama, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Maryland, Massachusetts, Mississippi, New Jersey, New York, North Carolina, Rhode Island, and South Carolina.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.